Vector-Based Gene Therapy and Gene-Editing Products Ongoing Clinical Trials Gene therapies are now a reality. They open new perspectives for the treatment and management of a wide range of rare and common diseases. We have listed ongoing clinical trials using viral vector and gene editing products to get a more…..
Record financing for the regenerative medicine sector through Q3 2020 The regenerative medicine sector attracted $15.9 billion in financing through just the first three quarters of the year, shattering the previous record of $13.5 billion Global financing for the regenerative medicine and advanced therapy sector set an annual record of…..
How to increase the number of European-based ATMP clinical trials? The latest report published by the Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader advanced therapies sector, shows that Europe has become less competitive than other regions in attracting new advanced…..
BioPharmAnalyses and OctopusyX BioConsulting are proud to announce the launch of their up-dated and enriched 2019 edition of their report entitled “Landscape… in Gene Therapy Companies”. This report provides you with an in-depth analysis of more than 230 companies involved in this expanding field. (UPDATED SEP 2019) In…..
300 million people living with a rare disease worldwide An open-access article, written by Orphanet (coordinated by INSERM, the French National Institute of Health and Medical Research), EURORDISRare Diseases Europe and Orphanet Ireland (based at the National Rare Diseases Office, Mater Misericordiae University Hospital, Dublin, Ireland), confirms the number of…..
Convergence of digital technology and healthcare – digital health – has become a key driver of change for healthcare systems globally, with the mass adoption of digital technologies set to revolutionise healthcare and patient wellbeing. Payors and healthcare and life science companies must learn from the mistakes made in other…..
Antibiotic development increased, but still insufficient While the pipeline of new antibiotics has improved over the past six years, momentum in the development of new infection-fighting agents remains inadequate and could take a significant downturn without new incentives, a report released in Clinical Infectious Diseases shows. This report, an update of progress…..
En 2017, le top 10 de l’industrie pharmaceutique a réalisé un chiffre d’affaires global de 322,76 milliards d’€ (+ 2,07 %) pour un bénéfice de 59,79 milliards d’€ (-14%). Ses dépenses de R&D ont atteint 64,4 milliards d’€ (+1,8%) tandis que le montant des dividendes versés aux actionnaires s’est élevé…..
Gene Therapy is a rapidly and obviously evolving field that is now definitively recognized as a well-acknowledged major medical and scientific area. BioPharmAnalyses is proud to announce the launch of its new global commercial report "Landscape in Gene Therapy Companies". This is the first such report that provides you with an actually updated information and an accurate international mapping…..
2017 restera probablement dans les annales comme un des meilleurs crus de la décennie en Europe et aux Etats-Unis. Après une année 2016 marquée par les incertitudes liées aux résultats des élections présidentielles américaines, la FDA a enregistré 42 nouvelles entités moléculaires (NEM) et produits biologiques, se rapprochant des niveaux…..